Xconomy
AUGUST 21, 2017
FDA Commissioner Scott Gottlieb has been very public in expressing his desire to provide increased competition and greater choice to American consumers in a bid to drive down prices of prescription medicines. Recently, the agency he oversees took some unusual steps to back up those statements with action.
Xconomy
SEPTEMBER 19, 2019
With the 2020 election just over a year away, House Speaker Nancy Pelosi (D-CA) has unveiled the Democratic Party’s answer to public discontent over high prescription drug prices. A preview of the plan was leaked last week. Today’s announcement doesn’t stray far. The new plan would have the U.S.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
JULY 6, 2018
Our friend and one of our earliest employees, San Diego editor Bruce Bigelow, died suddenly last weekend. Bruce covered everything—and everyone—in San Diego’s innovation scene, including the life sciences. Xconomy was dumbstruck this week, and not by the fireworks overhead.
TechCrunch LA
MARCH 20, 2019
The feature illustrates how Postmates, one of the earlier entrants to the billion-dollar food delivery wars , is trying to remain competitive by appealing to price-sensitive customers. Los Angeles, Miami, New York City, Phoenix, San Francisco, San Diego, Seattle, Orange County, Calif. and Philadelphia.
Xconomy
MAY 11, 2018
The administration’s “American Patients First” plan, released via a speech and an accompanying 38-page “blueprint” document , laid out some relatively modest actions aimed at spurring generic competition, making it easier for Medicare (the government-funded health program for seniors) to manage high drug costs and negotiate discounts, making drug prices (..)
Xconomy
MAY 10, 2019
The field has gotten so competitive that multiple products are on the market for some diseases. An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12 percent a year between now and 2024, when they will account for an estimated 20 percent of worldwide prescription drug sales.
Xconomy
JULY 26, 2019
He steered Vertex through a crisis when its hepatitis C business was squashed by competition. Vertex surprised Wall Street this week by announcing Leiden’s seven-year run will end next spring. In some ways, his legacy is already written.
Expert insights. Personalized for you.
55 
Let's personalize your content